We read the article entitled ''Bilirubin levels and the burden of coronary atherosclerosis in patients with STEMI'' by Sahin et al. 1 They observed that in patients with ST-segment elevation myocardial infarction (STEMI), serum bilirubin levels were higher in the high SYNTAX score (SS) group than in the low-SS group. The authors also reported a significant correlation between SS and bilirubin levels.
Several studies have suggested that bilirubin and its precursor biliverdin have the capacity to remove reactive oxygen radicals that play a role in atherogenesis. 2, 3 On the basis of this hypothesis, studies have focused on the association of several oxidative biomarkers such as bilirubin levels and coronary artery disease. 4, 5 But there are few studies reporting serum bilirubin levels in patients with STEMI undergoing primary percutaneous coronary intervention (PCI).
In a recent study, Celik et al 6 determined that serum bilirubin levels were independently associated with the development of postprimary PCI coronary no-reflow as well as increased inhospital major adverse cardiac events in patients with STEMI. It would be worthwhile to consider postprimary PCI thrombolysis in myocardial infarction flow grade and inhospital or long-term outcomes in patients with STEMI when dealing with correlation between the bilirubin levels and the burden of coronary atherosclerosis.
In Sahin et al's 1 study, exclusion criteria were treatment of STEMI in the previous 24 hours with thrombolytic drugs, active infection, systemic inflammatory disease, known liver disease, or renal failure. But we think that there should be some other exclusion criteria such as cardiogenic shock and congestive heart failure on admission, which may affect bilirubin levels during STEMI. Also, the blood samples for the laboratory analysis were drawn 24 hours after the completion of PCI, but extravasation is an important reason for increased bilirubin levels. 7 Because access site or other bleeding complications can be seen frequently in patients with STEMI undergoing PCI, samples obtained 24 hours following PCI are likely to be affected. Admission bilirubin levels would be important for providing an opportunity to observe the changes in bilirubin levels during STEMI. We believe that these findings will provide useful information about the relationship between the bilirubin levels and the burden of coronary atherosclerosis in patients with STEMI and will act as a guide for further studies.
